Table 1.
Baseline Characteristics of Patients With AF, According to First Prescribed OAC After Propensity Score Matching: MarketScan, 2010–2015
| Characteristics | Comparison of DOACs With Warfarin | Comparison Among Dabigatran, Rivaroxaban, and Apixaban | ||
|---|---|---|---|---|
| Warfarin | Dabigatran | Dabigatran | Rivaroxaban | |
| N | 31 304 | 31 304 | 18 057 | 18 057 |
| Age, mean (SD), y | 67 (13) | 67 (13) | 67 (12) | 66 (13) |
| Women, % | 35 | 35 | 35 | 34 |
| CHA2DS2‐VASc score, mean (SD) | 3.0 (2.0) | 3.1 (2.0) | 3.0 (2.0) | 2.9 (1.9) |
| HAS‐BLED score, mean (SD) | 1.8 (1.1) | 1.8 (1.2) | 1.7 (1.1) | 1.7 (1.1) |
| Warfarin | Rivaroxaban | Dabigatran | Apixaban | |
| N | 39 202 | 39 202 | 7125 | 7125 |
| Age, mean (SD), y | 68 (13) | 67 (13) | 67 (12) | 67 (13) |
| Women, % | 39 | 38 | 35 | 36 |
| CHA2DS2‐VASc score, mean (SD) | 3.1 (1.9) | 3.1 (1.9) | 3.0 (1.9) | 2.9 (1.9) |
| HAS‐BLED score, mean (SD) | 1.8 (1.1) | 1.8 (1.1) | 1.7 (1.1) | 1.7 (1.1) |
| Warfarin | Apixaban | Rivaroxaban | Apixaban | |
| N | 19 305 | 19 305 | 19 358 | 19 358 |
| Age, mean (SD), y | 69 (13) | 69 (13) | 69 (12) | 69 (13) |
| Women, % | 40 | 40 | 40 | 40 |
| CHA2DS2‐VASc score, mean (SD) | 3.4 (1.9) | 3.4 (2.0) | 3.3 (2.0) | 3.4 (2.0) |
| HAS‐BLED score, mean (SD) | 1.9 (1.1) | 1.9 (1.2) | 1.9 (1.2) | 1.9 (1.2) |
Comparison groups are matched 1:1. AF indicates atrial fibrillation; DOAC, direct oral anticoagulant.